Remove 2030 Remove Pharmaceutical Companies Remove Vaccines
article thumbnail

STAT+: Report: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players

STAT

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Scientific evidence ‘on demand’? Proceedings from an expert roundtable

pharmaphorum

Another recent change is the timelier release of scientific information; rather than holding on to clinical trial findings until the ‘perfect’ opportunity to present them at a major congress, 2020 increasingly saw pharmaceutical companies make data public in real time. What are the associated challenges? Conclusion.

article thumbnail

Greening India’s industrial horizon: Navigating climate resilience in pharma and beyond

Express Pharma

India’s pharmaceutical industry is a global powerhouse. It is already a massive $50 billion market and is projected to grow to $130 billion by 2030. India makes 60 per cent of the world’s vaccines and 20 per cent of the world’s generic drugs. who have sustainability ambitions will also pressure the sector to go green.

article thumbnail

Pharma sector awaits Budget 2024 for innovation boost and regulatory reforms

Express Pharma

The government’s initiative to implement a draft strategy aimed at promoting innovation, R&D, and industry-led innovation growth in India’s MedTech and Pharmaceutical industries is a welcome move. This would stimulate new investments in both R&D and production initiatives.

article thumbnail

BioNTech pledges major UK investment

European Pharmaceutical Review

It is one of the biggest investments in UK history for a pharmaceutical company. The multi-year partnership with the UK government aims to provide up to 10,000 patients with investigational personalised cancer immunotherapies by 2030, according to the UK governments Department for Science, Innovation and Technology (DSIT).

article thumbnail

Could virtual reality become an essential tool for healthcare education?

pharmaphorum

Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.

Vaccines 145